FDA Grants Priority Review to Infigratinib to Treat Cholangiocarcinoma



The agent’s new drug application will be reviewed under the FDA’s Real Time Oncology Review pilot program and under Project Orbis.

The FDA accepted and granted priority review to the new drug application (NDA) for infigratinib to treat patients with cholangiocarcinoma, according to BridgeBio Pharma, Inc., an affiliate QED Therapeutics.

“We want to thank the patients, families, scientists, physicians and all others involved who helped us move this NDA forward. At BridgeBio we believe that every minute counts for patients and their families, and we are eager to help as many people suffering from cholangiocarcinoma as possible – as quickly as possible,” Neil Kumar, PhD, CEO and founder of BridgeBio, said in a press release.

The NDA is being reviewed under the Real-Time Oncology Review (RTOR) pilot program, which is designed by the FDA’s Oncology Center of Excellence to expedite the delivery of safe and effective cancer treatments to patients. Moreover, the company will be submitting the agent for review in Australia and Canada under Project Orbis, another initiative from the FDA’s Oncology Center of Excellence, to allow for concurrent submission and review of oncology drugs among participating international regulatory agencies.

Infigratinib is an oral FGFR1-3 selective inhibitor aimed to treat patients with FGFR-driven conditions, including cholangiocarcinoma, urothelial carcinoma, and achondroplasia. FGFR2 genetic aberrations are present in approximately 15% to 20% of people who have cholangiocarcinoma – a disease with limited treatment options and a 5-year survival rate of only 9%.


BridgeBio Pharma, Inc. BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma. Published: December 1, 2020. https://bridgebio.com/news/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug-application-for-infigratinib-for-the-treatment-of-cholangiocarcinoma. Accessed: December 1, 2020.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content